Trial Profile
A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Amgen
- 01 Jun 2020 Results of integrated analysis of five clinical trials evaluating the efficacy and safety of romiplostim self-administration published in the American Journal of Hematology
- 24 Jun 2014 New trial record